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A b s T r A C T
Thyroid function disorders are common with a female 
to male ratio of 4 to 1. in adult women primary 
hypothyroidism and thyrotoxicosis have a prevalence of 
3.5/1000 and 0.8/1000, respectively. This guideline is 
aimed at secondary care providers especially internists, but 
also contains relevant information for interested general 
practitioners and gynaecologists. A multidisciplinary 
working group, containing delegates of professional and 
patient organisations, prepared the guideline. According to 
principles of ‘evidence-based medicine’ available literature 
was studied and discussed. Considering the availability 
and quality of published studies a practical advice was 
formulated. for a full overview of the literature and 
considerations the reader is referred to the original version 
of the guideline (accessible through NiV-net). in this 
manuscript we have aimed to provide the practicing 
internist with practical and ‘as evidence-based as possible’ 
treatment guidelines with respect to thyroid function 
disorders.
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Hyperthyroidism, hypothyroidism, thyroid function, 
thyroxine
i N T r o d U C T i o N
Thyroid function disorders are common with a 
female-to-male ratio of 4 to 1. In adult women primary 
hypothyroidism and thyrotoxicosis have a prevalence of 
3.5/1000 and 0.8/1000, respectively.1 
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This guideline is aimed at secondary care providers, especially 
internists but also contains relevant information for interested 
general practitioners and gynaecologists. A multidisciplinary 
working group prepared the guideline. The members of the 
working group were delegates of their respective professional 
organisations and a delegate of the patient organisations was 
also a full member of the working group. 
According to principles of evidence-based medicine available 
literature was studied and discussed. Considering the 
availability and quality of published studies, a practical 
advice was formulated. For a full overview of the literature 
and considerations, the reader is referred to the original 
version of the guideline (accessible through NIV net). In this 
manuscript we have aimed to provide the practising internist 
with practical and ‘as evidence-based as possible’ treatment 
guidelines with respect to thyroid function disorders. 
d i A G N o s i s  o f  T H y r o i d  f U N C T i o N 
d i s o r d E r s
With regard to thyroid function disorders determination of 
the plasma thyroid-stimulating hormone (TSH) level is the 
single most important measurement.2 Figure 1 shows the 
algorithm for the diagnosis of thyroid function disorders. 
It is important to recognise that analytical problems can 
occur, most frequently due to concomitant medication (table 
1). The algorithm is most useful in an ambulant setting. In 
case of a serious – nonthyroidal – illness thyroid function 
measurements are frequently abnormal and normalise during 
recovery of the underlying illness.3 Therefore, in patients with 
(severe) illness, thyroid function should be determined only 
in cases with a very high index of suspicion.3
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Table 1. Analytical problems due to concomitant 
medication
Inhibition of TSH secretion Dopamine, glucocorticoids, 
somatostatin analogues
Inhibition of T4 secretion Amiodarone, lithium
Stimulation of T4 secretion Iodide, amiodarone
Impaired T4 absorption Biliairy salts, iron, antacids, 
calciumcarbonat, aluminium 
hydroxyde, sucralfate
Stimulation of TBG synthesis Oestrogens, opioids
Inhibition of TBG synthesis Androgens, glucocorticoids
Inhibition of 5’ deiodinase Amiodarone, b-blockers, 
glucocorticoids
TBG-T4 dissociation Frusemide, heparin
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After a descriptive diagnosis of a thyroid function disorder 
determination of thyroid autoantibodies or thyroid 
scintigraphy can be helpful in establishing the exact cause 
of the thyroid function disorder. This is especially prudent 
in case of thyrotoxicosis. 
T r E A T M E N T  o f  T H y r o T o x i C o s i s
There are three main causes of thyrotoxicosis: Graves’ 
disease, toxic uni- or multinodular goitre and thyroiditis. 
Available treatment options are medical therapy, 
radioactive iodine and surgical treatment. Because the 
preferred treatment differs according to the cause of 
the thyrotoxicosis, it is important to establish a causal 
diagnosis. Unless the cause of the thyrotoxicosis is obvious 
– e.g. in case of severe Graves’ orbitopathy – thyroid 
scintigraphy is thus advised in all cases of thyrotoxicosis.
How to do it box 1
Thyrotoxicosis: treatment options
Graves’ disease: medical, radioactive iodine, surgery• 4
Toxic nodular goitre: radioactive iodine, surgery• 5
Destructive thyrotoxicosis (subacute granulomatous • 
thyroiditis, postpartum thyroiditis): wait and see, 
symptomatic treatment6
Graves’ disease - treatment of thyrotoxicosis
Unless the thyrotoxicosis is very severe or a very large 
goitre is present, medical therapy is preferred for most 
patients.7 Surgery can be especially useful in case of a very 
large goitre or if severe orbitopathy is present.8 A high 
thyrotropin antibody titre is associated with a lower chance 
of permanent remission.9,10 
Based upon the available literature propylthiouracil (PTU) 
and methimazole seem equally effective as antithyroid 
figure 1. Diagnosis of thyroid function disorders
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drugs and no difference in the incidence of common adverse 
reactions (rash, arthralgia, gastrointestinal disturbances 
and altered taste) has been reported.11-14 However, more 
severe and uncommon side effects such as hepatitis and 
ANCA-positive vasculitis are more frequently associated 
with PTU than with methimazole.15 Also, methimazole 
can be dosed once daily improving compliance.13 It should 
be noted here that both PTU and methimazole can lead to 
life-threatening agranulocytosis; therefore, in case of sore 
throat in combination with fever the use of these drugs 
should be postponed until agranulocytosis is excluded. 
Taken together we advise methimazole as antithyroid drug 
of choice in nonpregnant adults. 
A recent meta-analysis concluded that with respect to 
reaching euthyroidism a block-and-replace (high-dose 
antithyroid) regimen is as effective as a titration (low-dose 
antithyroid) regimen.16 After a treatment period of six to 
18 months the relapse rates were 51% after a block-and-replace 
regimen and 54% after a titration regimen.16 The incidence of 
adverse reactions is only marginally higher for block-replace 
regimens; surprisingly, this was found for minor but not for 
major adverse reactions.16 We advise – based upon a more 
predictable lowering of thyroid hormone levels – a block-and-
replace regimen for 12 to 18 months above a titration regimen 
in the treatment of Graves’ disease in nonpregnant adults. 
How to do it box 2
Graves’ disease: medical therapy of thyrotoxicosis
Methimazole starting dose 30 mg once daily• 15,17,18
Check free thyroxine after 4-6 weeks, if in normal • 
range add L-thyroxine full replacement dose 
Adjust L-thyroxine dose on the basis of thyroid function • 
test results every 6-8 weeks. If test on two consecutive 
visits stable check thyroid function every 3 months
Stop methimazole and L-thyroxine after 12-18 • 
months19-22
A relapse of Graves’ disease – after previous medical 
treatment – should preferably be treated with radioactive 
iodine.23 In young patients with no cardiovascular history 
and a mild thyrotoxicosis, radioactive iodine can be given 
without previously rendering the patient euthyroid. In 
elderly patients and in those with a cardiovascular history 
it is advised to pretreat with antithyroid drugs until 
euthyroidism is achieved before treatment with radioactive 
iodine. Methimazole should be stopped three to five 
days and PTU at least 15 days prior to radioactive iodine 
treatment.24-28 After treatment with radioactive iodine, 
antithyroid drugs should not be restarted within four 
days after treatment.29 In order to prevent a worsening of 
symptoms – due to destruction of thyroid tissue –antithyroid 
treatment should be continued until at least three months 
after radioactive iodine treatment.30 The risk of permanent 
hypothyroidism depends on the administered radioiodine 
dose.31 In about 10% of patients the hypothyroidism that 
ensues after treatment with radioactive iodine is transient; 
therefore, it is advised that this is stopped six months after 
starting thyroxine supplementation for determination of 
TSH.32 Radioactive iodine should be considered as primary 
therapy for Graves’ disease in case of a large goitre or an 
unusually severe thyrotoxicosis.7
How to do it box 3
Graves’ disease: radioactive iodine treatment
In elderly patients and in those with a cardiovascular • 
history pretreat until euthyroidism is achieved
Stop methimazole 3-5 days and PTU at least 15 days • 
prior to radioactive iodine treatment24-28
In case of post-I• 131 hypothyroidism stop thyroxine 6 
months after starting in order to diagnose transient 
post-I131 hypothyroidism32
Surgical therapy for Graves’ disease should be considered 
in case of severe allergic reactions on antithyroid drugs, if 
malignancy of the thyroid is suspected and if restoration of 
euthyroidism needs to be achieved very quickly (e.g. in case 
of severe mechanical complaints.8 Operative management 
should consist of subtotal or near total thyroidectomy.8 
Preoperatively, the patient should be rendered euthyroid. 
Typical complications – depending on the surgeons 
experience – are hypopara thyroidism and damage to the 
laryngeal recurrent nerve.8
How to do it box 4
Graves’ disease: preoperative treatment
Standard: usual antithyroid therapy until euthyroidism • 
is restored (see box 2)
Allergic to antithyroid drugs: • 
- b-blocker until heart rate during exercise <80 /min: 
propranolol 80-240 mg daily
- Iodide: start 10-14 days preoperatively: KI 50-250 mg 
thrice daily (1-5 drops solutio iodi spirituosa) or solutio 
iodi aquosa (Lugol’s solution) 0.1-0.3 ml thrice
 daily (3-5 drops)
Graves’ disease - treatment of orbitopathy
Graves’ orbitopathy (GO) is associated with hyperthyroidism 
in 87% of patients.33 Three percent of patients with GO are 
hypothyroid and 10% are euthyroid. TSH-receptor antibodies 
are usually present and hyperthyroidism develops in about 
25% within years.33 In those with hyperthyroidism GO 
presents before thyrotoxicosis in 20%, during thyrotoxicosis 
in 40% and after thyrotoxicosis in 40%.33 Conversely, of all 
patients with Graves’ thyrotoxicosis only 5 to 15% develop 
serious GO and 30 to 40% mild GO.33 GO is usually bilateral; 
however, in 15% the orbitopathy is unilateral. Indeed, GO is 
the most prevalent cause of unilateral exophthalmos.33 In 
patients with GO quality of life is severely impaired.34,35   
Restoration of euthyroidism generally leads to improvement 
of GO.36,37 Considering the effects on GO, medical and 
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surgical treatment of the thyrotoxicosis are equally safe; 
radioactive iodine treatment, however, may exacerbate GO 
in 15% of patients.38,39 Such exacerbation occurs in the first 
few months after 131-I treatment; fortunately, in two-thirds 
of patients eye symptoms are mild and transient. Steroids 
can prevent exacerbation of GO after radioactive iodine 
treatment and is advised in patients with pre-existent 
active GO, serious thyrotoxicosis (TT3 >5 nmol/l), high 
TSH-receptor antibody titres and smokers.38,40,41 
How to do it box 5
Graves’ disease: radioactive iodine treatment – preventive 
treatment with steroids
Week 1-4: Prednisone 30 mg once daily• 
Week 5-8: Prednisone 20 mg once daily• 
Week 9-12: taper prednisone with 5 mg weekly• 
With respect to lifestyle, all patients with GO should be 
advised to quit smoking as this is associated with – more 
severe – GO and treatment failure.38,42,43
In order to further tailor immunosuppressive and surgical 
treatment, it is important to classify the severity and 
activity of GO. To this aim use of the clinical activity and 
NO-SPECS score is advised. For practical guidance and 
visual support see www.eugogo.org. 
How to do it box 6
GO activity: Clinical Activity Score (amended from 
Mourits et al. Br J Ophthalmol 1989,73,639-4
Spontaneous orbital pain • 
Gaze evoked orbital pain• 
Eyelid swelling that is considered to be due to active • 
(inflammatory phase) GO 
Eyelid erythema • 
Conjunctival redness that is considered to be due to • 
active (inflammatory phase) GO (ignore ‘equivocal’ 
redness)
Chemosis • 
Inflammation of caruncle or plica • 
Increase of • >2 mm in proptosis 
Decrease in uniocular excursion in any one direction • 
of >8° 
Decrease of acuity equivalent to 1 Snellen line • 
 
How to do it box 7
GO severity: NO SPECS score
0. No symptoms or signs of GO
1. only signs, no symptoms
2. soft tissue involvement (aperture in mm)
3. Proptosis (Hertel in mm)
4. Extraocular muscle involvement (motility, double 
vision)
5. Corneal involvement
6. Sight loss (visual acuity, colour vision)
Mild GO can be treated with retrobulbar radiotherapy. This 
is especially effective in pain control and improving motility 
but has no effect on proptosis.44,45 GO of intermediate 
severity can be treated with immunosuppressants (preferably 
with intravenous steroids).44,45 Severe GO characterised by 
optical neuropathy and corneal ulceration represents the 
most severe manifestation of GO and should be treated 
with either high-dose steroids or orbital decompressive 
surgery.44,45 It is strongly advised to refer patients in whom 
immunosuppressive or orbital decompression surgery is 
contemplated to specialist centres. 
iodine-induced thyrotoxicosis
Iodine excess can lead to thyrotoxicosis. Iodine intake in 
the Netherlands is adequate (i.e. 150 to 300 mg/day).46 In 
vulnerable people such as those with a history of Graves’ 
disease or with nodular goitre, excess iodine can lead to 
thyrotoxicosis: iodine-induced thyrotoxicosis (IIT).47 Common 
sources of excess iodine are: iodine-containing radiographic 
contrast agents, amiodarone, kelp, iodine-containing 
multivitamins and large quantities of Japanese food.47 IIT 
due to iodine-containing radiographic contrast agents and 
amiodarone will be discussed in more detail.
IIT after administration of radiographic contrast agents 
occurs in 0 to 1.2% of patients without underlying thyroid 
disease.48 In patients with an underlying thyroid disorder 
the incidence is 5.2%.48-51 Risk factors are higher age, 
nodular goitre and suppressed TSH.48 The thyrotoxicosis 
is usually mild and resolves spontaneously. Prevention is 
possible with methimazole (20 mg once daily) and sodium 
perchlorate (300 mg thrice daily).52-54 Despite treatment 
thyrotoxicosis is not preventable in all patients and side 
effects are common.52,54 Therefore preventive treatment 
should be considered only in those patients at high risk for 
serious cardiac arrhythmia. 
How to do it box 8
Prevention of contrast agent induced thyrotoxicosis
Methimazole once daily 20 mg and sodium perchlorate 
three times daily 300 mg
 
Amiodarone administration has several effects on 
parameters of thyroid function. Amiodarone consists for 
39.3% of iodine. A dose of 200 to 400 mg daily therefore 
leads to a substantial iodine excess. Such an excess leads to 
inhibition of thyroid iodine organification (Wolff-Chaikoff 
effect) resulting in an increase in TSH (resulting in 
a TSH of about 5 to 15 mU/l) which – due to escape of 
Wolff-Chaikoff effect – normalises after approximately 
three months. Peripheral effects of amiodarone on thyroid 
hormone metabolism collectively lead to higher T4 and 
fT4 levels while TSH remains normal. During amiodarone 
use the upper limit of normal for T4 and fT4 should be 
increased by about 25%.
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In the Netherlands amiodarone-induced thyrotoxicosis 
(AIT) occurs in 12.1% of amiodarone-treated patients.55 The 
clinical picture shows a wide variety; often the presenting 
symptom is worsening of cardiac arrhythmia.56,57 
Development of AIT is not associated with cumulative 
dose. It occurs unpredictably and in a short period of 
time.55 There are two types of AIT: type I and type II. 
As treatment differs it is important to carefully evaluate 
patients with AIT. 
Type I is a thyrotoxicosis with hyperthyroidism occurring 
in patients with nodular goitre or Graves’ disease. Thyroid 
antibodies are frequently present. As a result of increased 
thyroid hormone synthesis radioactive iodine uptake can 
still be increased and the thyroid is hypervascularised.56 
Type II is a destruction-mediated thyrotoxicosis that 
results from the cytotoxic effect of amiodarone on thyroid 
follicular cells.56
Treatment can be difficult.56,57 Type I AIT is preferably 
treated with methimazole 30 mg daily in combination with 
potassium perchlorate 500 mg twice daily.56,58 As excess 
iodine renders methimazole less effective, methimazole 
alone does not significantly shorten the period of 
thyrotoxicosis in most patients. It is advised to stop 
administration of amiodarone if possible; unfortunately 
most patients are still thyrotoxic six to nine months after 
discontinuation of amiodarone. Radioactive iodine uptake 
is sometimes high enough to make radioactive iodine 
therapy possible. In case of type II AIT the treatment 
of choice is prednisone: 30 mg daily for two weeks and 
thereafter tapering to zero in three months.59 In type II 
AIT continuation of amiodarone is usually possible.60 In 
extremely therapy resistant cases thyroidectomy can be 
an option.61 
How to do it box 9
Treatment of AIT
Type I: methimazole 30 mg daily in combination with • 
potassium perchlorate 500 mg twice daily. If possible 
stop amiodarone
• Type II: prednisone: 30 mg daily for two weeks and 
thereafter tapering to zero in 3 months. Continuation 
of amiodarone usually possible
subclinical hyperthyroidism
Subclinical hyperthyroidism is a biochemical diagnosis 
characterised by suppressed TSH and normal free T4 and 
T3 concentrations.62 When other causes of suppressed 
TSH – medication (steroids, dopamine), nonthyroidal 
illness, (supra) sellar disease – are excluded a suppressed 
TSH is indicative of a T4 concentration that is above the 
individually determined setpoint.
The prevalence of endogenous subclinical hyperthyroidism 
is 0.7 to 1.9%, of exogenous hyperthyroidism 1.3 to 
2.0%.63,64 Causes are nodular goitre, Graves’ disease and 
thyroiditis.
Subclinical hyperthyroidism is statistically associated 
with atrial fibrillation: in subjects in the Framingham 
heart study with a TSH <0.1 the cumulative ten-year 
incidence for atrial fibrillation was 28% compared with 
11% in those with normal TSH levels.64 These findings 
were recently confirmed by Capolla et al. who found in 
persons with a TSH <0.4 mU/l during a period of 13 years 
a twofold increased incidence of atrial fibrillation compared 
with euthyroid subjects.65 Besides rhythm disturbances 
subclinical hyperthyroidism also leads to adverse changes 
in echocardiographic measurements.66 In postmenopausal 
women subclinical hyperthyroidism is associated with 
osteoporosis.67 With regard to fractures it can be said that 
women with a suppressed TSH have a higher fracture 
incidence than women with a normal TSH.68 Finally, the 
risk of dementia seems threefold increased in subclinical 
hyperthyroidism.69 However, whether there is an increased 
mortality in patients with subclinical hyperthyroidism is 
controversial. 
Based on the above it is advised to treat patients with 
subclinical hyperthyroidism if there are toxic symptoms, 
atrial fibrillation or osteopenia.70 Regardless of signs and 
symptoms it should be considered to treat persons older 
than 60 years, postmenopausal women especially if TSH 
is <0.1 mU/l. 
Thyroiditis 
Thyroid inflammation can be caused by physical 
stimuli, micro-organisms and autoimmunity.6 Subacute 
granulomatous thyroiditis and subacute lymphocytic 
thyroiditis will be discussed here. Postpartum thyroiditis 
will be reviewed separately. 
Subacute granulomatous thyroiditis (Quervain’s 
thyroiditis)71 has an incidence that is one-fifth to one-eight 
of that of Graves’ disease and is more common in 
women.72,73 It is assumed that it is caused by a virus or 
by post-viral inflammation.6 Thyroiditis presents with 
pain in the thyroid region often radiating to the ear 
accompanied by muscle pain, fatigue and symptoms of 
thyrotoxicosis.74-76 Physical examination reveals a painful 
goitre.74,76 In the acute phase the erythrocyte sedimentation 
rate is elevated (typically >40 mm) with slight anaemia and 
leucocytosis.74,77 Thyroid function shows a thyrotoxicosis 
lasting two to ten weeks that resolves spontaneously.74,77,78 
The thyrotoxicosis is destruction mediated and is therefore 
self-limiting, treatment is symptomatic with aspirin (600 
mg three to six times daily) and b-blockers.74,77,79 In rare 
cases treatment with steroids (one week of prednisone 
40 mg daily, then 30 mg to be tapered by 5 mg weekly) is 
needed to control pain.77,80 There is no increased risk for 
development of permanent overt hypothyroidism.6
139
m a r c h  2 0 0 8 ,  V o l .  6 6 ,  N o .  3
Muller, et al. Thyroid function disorders.
How to do it box 10
Symptomatic treatment of subacute granulomatous 
thyroiditis
Aspirin 600 mg three tot six times daily • 
•	 b-blockers e.g. propranolol 40-120 mg or atenolol 25-50 
mg daily
Subacute lymphocytic thyroiditis and postpartum 
thyroiditis are generally considered to be variants of 
Hashimoto’s thyroiditis.6 It is an autoimmune destructive 
thyrotoxicosis.6 Contrary to subacute granulomatous 
thyroiditis it is painless and classically has a biphasic 
course: a thyrotoxicosis followed by a hypothyroid 
period.6 As in subacute granulomatous thyroiditis the 
thyrotoxic phase is destruction mediated and self-limiting.6 
However, unlike subacute granulomatous thyroiditis 
permanent hypothyroidism develops in 6%. Importantly, 
hypothyroidism can develop after a prolonged period of 
euthyroidism. Therefore, yearly assessment of thyroid 
function is advised.6 
T r E A T M E N T  o f  P r i M A r y 
H y P o T H y r o i d i s M
Primary overt hypothyroidism
Primary hypothyroidism is caused by a thyroid disorder 
and biochemically characterised by an elevated TSH and a 
lowered fT4.81 Symptoms are usually vague and nonspecific, 
frequently occurring symptoms are cold intolerance, 
constipation, dry skin, low heart rate, hoarse voice and 
impaired mental performance.82 In its most extreme 
form heart failure and coma can occur.82 In children 
hypothyroidism can cause mental retardation; indeed, 
worldwide hypothyroidism caused by iodine deficiency is the 
single most prevalent cause of mental retardation.83 
The prevalence of hypothyroidism is 0.3 to 0.4%, increasing 
with age and with a female predominance.63,84,85 Usually it 
is on autoimmune basis. Other causes are iatrogenic (after 
previous treatment for hyperthyroidism), medication 
(amiodarone, lithium) and congenital.82,86 Worldwide, 
iodine deficiency is by far the most prevalent cause of 
hypothyroidism.82
Treatment is substituting the deficient hormone, i.e. 
L-thyroxine.82,87 Dose is dependent on underlying cause and 
weight, around 1.8 mg/kg for autoimmune hypothyroidism 
and about 2.0 mg/kg after (near) total thyroidectomy.82 
However, interindividual variance is large. In young and 
healthy patients full-dose substitution can be given at once.82 
However, in the elderly (arbitrarily defined as >60 years) 
and those with cardiovascular morbidity it is advised to start 
more slowly (25 mg with dose adjustments based on TSH 
every four to six weeks). Importantly, there are no differences 
in quality of life between a fast and slow titration schedule.88 
Thyroid hormone dose is adjusted on the basis of TSH – not 
fT4 – aiming for a TSH in the normal range.87 L-thyroxine 
should be taken either in the morning on an empty stomach 
or in the evening at bedtime, in the last instance the required 
dose to reach euthyroidism is generally lower.89 
Several drugs such as biliary salts, iron, antacids, calcium 
carbonate, aluminium hydroxyde and sucralfate interfere 
with thyroxine uptake.90-95 It is advised to take these 
medications two to four hours apart from thyroxine. 
Phenytoin, carbamazepine, fenobarbital and rifampicin 
lead to an increased clearance of thyroxine, thus the need 
for thyroxine increases.96-99 
Persistent symptoms after biochemically optimal 
substitution: T4/T3 combination therapy
A substantial number of treated patients have persistent 
symptoms despite biochemically optimal substitution.100,101 
Possibly this is because of a lack of T3 produced by the 
thyroid.82
In a recent meta-analysis of 11 studies with a total of 1216 
randomised patients no significant differences with respect 
to body pain, depression, fear, quality of life and lipids 
were noted between T4/T3 combination therapy and T4 
therapy.102 In a large Dutch study patients preferred T4/
T3 combination therapy in a 5:1 ratio.103 Surprisingly this 
preference was not reflected in a battery of neurocognitive 
tests. What was related to this patient preference was 
weight loss. In the dose the patients preferred (T4/T3 in 
a ratio 5:1) 51% of the patients had a suppressed TSH, a 
higher heart rate and elevated bone markers. Based on the 
above T4/T3 combination therapy is not advised as standard 
therapy for primary hypothyroidism.103 
In case of persistent symptoms after biochemically optimal 
substitution it is reasonable – albeit not supported by 
evidence – to increase the substitution dose until the 
TSH is low normal. Also, it is important to exclude other 
diseases that are associated with primary – autoimmune – 
hypothyroidism, such as type I diabetes mellitus, adrenal 
insufficiency, vitamin B12 deficiency and celiac disease. 
How to do it box 11
Treatment of primary hypothyroidism
Young and healthy patients: L-thyroxine full dose • 
substitution: 1.8 mg/kg for autoimmune hypothyroidism 
and about 2.0 mg/kg after (near) total thyroidectomy
Elderly (arbitrarily defined as >60 years) patients and • 
those with cardiovascular morbidity: titrate more slowly: 
25-50 mg starting dose
Dose adjustments based on TSH every 4-6 weeks, aim • 
for TSH in normal range
When stable check TSH once yearly• 
• In case of persistent symptoms titrate TSH to low 
normal levels, exclude diseases that are associated with 
autoimmune hypothyroidism
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subclinical hypothyroidism
Subclinical hypothyroidism is defined as the situation in 
which TSH is elevated and fT4 is normal.70 Alternative 
causes for such a biochemical profile are nonthyroidal 
illness, recovery from thyroiditis and treatment with 
recombinant TSH.104 The prevalence varies between 4 and 
8.5%.70
The risk for development of overt hypothyroidism is 
positively associated with TSH and the presence of TPO 
antibodies. If TSH is <6.0 mU/l the cumulative risk 
for development of overt hypothyroidism is close to 
zero, if TSH is between 6 and 12 mU/l this is 42.8%, 
and with a TSH >12 mU/l the cumulative incidence of 
overt hypothyroidism is 76.9%.105 The presence of TPO 
antibodies can add in assessing the risk for development 
of overt hypothyroidism, especially if the TSH is between 
6 and 12 mU/l; in this range the risk for development of 
overt hypothyroidism increases by 80%.105 Outside this 
range the risk for development of overt hypothyroidism 
increases by 40%.105
There is one study on cardiovascular morbidity and 
mortality that shows no increased cardiovascular risk in 
patients with subclinical hypothyroidism followed for 20 
years.106 However, two recent meta-analyses did show that 
subclinical hypothyroidism is associated with coronary 
heart disease.107,108
Unfortunately there are no intervention studies of sufficient 
quality that show a positive effect of treatment.109-113 Despite 
this shortcoming it seems defendable to start a trial of 
treatment of at least three months in case of otherwise 
unexplained fatigue or cognitive dysfunction in patients 
with subclinical hypothyroidism. It should be noted that 
in those older than 85 years the presence of subclinical 
hypothyroidism is associated with a lower mortality.114 
lithium-induced hypothyroidism 
In about 50% of lithium-treated subjects a goitre 
develops.115-118 This is most likely caused by elevated TSH 
levels as subclinical and overt hypothyroidism are seen in 
20 to 30% and 4.4% of cases respectively.66,115,119 Therefore, 
in case of lithium use we advise checking TSH every six to 
twelve months;119 and – in order to prevent goitre formation 
– prescribe thyroxine if the TSH is >4.0 mU/l. 
T H y r o i d  d y s f U N C T i o N  d U r i N G 
P r E G N A N C y  A N d  P o s T P A r T U M
During pregnancy maternal thyroid hormone metabolism 
changes considerably.120 There is an increase in iodine 
demand due to placental transport to the foetus.83 Daily 
iodine intake during pregnancy and lactation should 
therefore be at least 250 mg.83 
Under the influence of oestrogen, thyroxine-binding 
globulin (TBG) levels increase considerably; this leads 
to an increase in TT4 and TT3 concentrations.120 In the 
first trimester hCG levels rise sharply and – due to the 
structural homology of hCG and TSH and their respective 
receptors – lead to a lowering of TSH (<0.4 mU/l in 10% 
of pregnancies).120 Also, there is considerable placental 
thyroxine transport which adds to the increased thyroid 
hormone requirement during pregnancy.120 
As the foetal pituitary-thyroid axis becomes functional 
around week 12 of gestation it follows that before this 
period the foetus is completely dependent upon maternal 
supply of thyroid hormone.121 
Hyperthyroidism during pregnancy is most often due to 
gestational transient hyperthyroxinaemia. This occurs in 
2 to 3% of European women and in 11% of Asian women. 
Graves’ disease is seen in 0.01 to 0.02% of pregnancies.122 
As untreated or poorly treated hyperthyroidism is 
associated with obstetric complications (miscarriage, 
low birth weight, (pre)-eclampsia and possibly congenital 
malformations) and – in case of Graves’ disease – with 
foetal and neonatal thyrotoxicosis adequate diagnosis and 
treatment are essential.123-126  
Gestational transient hyperthyroidism occurs in the 
first trimester and is associated with hyperemesis in 
50% of cases.127,128 Women with gestational transient 
hyperthyroidism usually have no goitre, lack signs of 
thyroid eye disease and TSH receptor antibodies (TRAb) 
are negative. The thyrotoxicosis is usually mild, and 
resolves spontaneously by week 18 in most cases.127,128 
Graves’ disease should be suspected in the presence of a 
diffuse goitre, ophthalmopathy, thyroid dermopathy and 
the presence of TRAb. In women with known Graves’ 
disease who are contemplating pregnancy the disease 
should preferably be treated by thyroid ablation either with 
radioactive iodine or surgery before pregnancy. It should 
be noted that for six months after radioiodine treatment 
pregnancy is contraindicated and euthyroidism is not 
always restored after one treatment. 
Graves’ disease diagnosed during pregnancy should 
be treated medically. Medical treatment of Graves’ 
disease during pregnancy consists of monotherapy with 
antithyroid drugs in the lowest possible dose to achieve a 
fT4 concentration in the high normal range.120 Because 
there are reports linking methimazole use with aplasia 
cutis, choanal atresia and oesophagus atresia there is a 
preference for the use of PTU.129,130 It is advised to perform 
thyroid function tests every six to eight weeks.120 Often 
it is possible to stop treatment in the third trimester.120 
In exceptionally resistant cases thyroidectomy should be 
considered in the second trimester. During lactation it is 
safe to use methimazole (<20 mg daily) or PTU (<300 mg 
daily).
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The risk of foetal and neonatal thyrotoxicosis can and 
should be assessed by the measurement of maternal 
serum TRAb.131 It is advised to measure these antibodies 
in all women with (a history of) Graves’ disease. This is 
especially relevant in women rendered hypothyroid as 
a result of ablative therapy for Graves’ disease.131 TRAb 
can be measured in the first or second trimester and if 
positive should be measured again in the third trimester.131 
If TSH-receptor antibodies are present in the third 
trimester adequate monitoring for foetal thyrotoxicosis is 
mandatory.131 
Relevant literature suggests that even relatively mild and 
often unrecognised maternal hypothyroxinaemia (i.e. 
low fT4 and normal TSH) is associated with significant 
and persistent impairment of neuropsychological 
performance in the offspring.132,133 Unfortunately there 
are no prospective studies available on the effects of 
thyroxine supplementation regarding the long-term 
neurodevelopment of the infant. Moreover, determining 
free thyroxine levels in pregnancy has serious analytical 
shortcomings.120 So, it is at present unclear how to proceed 
when the fT4 is low but TSH is normal. 
In case of an elevated TSH – i.e. >4.0 mU/l – a significantly 
increased rate of obstetrical complications has been 
described.134,135 Therefore, it is advised to treat subclinical 
hypothyroidism (TSH >4.0 mU/l) in pregnancy. Whether 
in case of otherwise unexplained infertility or habitual 
abortion, treatment of subclinical hypothyroidism has 
favourable results is unknown. However, based on the 
above it seems reasonable at least to consider thyroxine 
treatment. 
Overt hypothyroidism (raised serum TSH and decreased 
free thyroxine) diagnosed during pregnancy should be 
immediately treated with full replacement doses of T4.120 
In women preconceptionally treated, T4 requirements 
during pregnancy increase on average by 50%.120,136 Women 
with subclinical hypothyroidism should be advised to have 
thyroid function tests as soon as they have a positive 
pregnancy test. Women who are already using thyroxine 
should be instructed to increase their dosage by 30%; 
thereafter, dosage should be adjusted based upon thyroid 
function tests.136,137 As in the treatment of hyperthyroidism 
it is advised to perform thyroid function tests every six to 
eight weeks aiming for a TSH between 1 and 2 mU/l.136,137 
How to do it box 12
Treatment of Graves’ disease during pregnancy
Monotherapy with PTU in the lowest possible dose • 
Aim for a normal TSH and a fT4 concentration in the • 
high normal range
Adjust dose every 4-6 weeks• 
• Check TSH-receptor antibodies in mother
 
How to do it box 13
Treatment of hypothyroidism during pregnancy
In pregnancy treat subclinical hypothyroidism (TSH • 
cut-off >4.0 mU/l)
Treat overt hypothyroidism diagnosed during pregnancy • 
immediately with full replacement doses of T4 
If hypothyroid preconceptionally: instruct to increase • 
dosage by 30% if pregnancy is diagnosed
Aim for a normal TSH and a fT4 concentration in the • 
high normal range
• Adjust dose every 4-6 weeks
P o s T P A r T U M  T H y r o i d i T i s
Postpartum thyroiditis is a syndrome of transient or 
permanent thyroid dysfunction occurring in the first year 
after delivery, based on an autoimmune inflammation of 
the thyroid.138 In the Netherlands the incidence is reported 
from 5.2 to 7.2%.138 Postpartum thyroiditis classically 
runs a biphasic course: a thyrotoxic phase is followed by a 
hypothyroid phase. ‘Postpartum’ thyroiditis can also occur 
after loss of pregnancy at 5-20 weeks gestation.138
The thyrotoxic phase of postpartum thyroiditis is due to 
leakage of thyroid hormones from destroyed thyrocytes and 
is therefore self-limiting. The most important differential 
diagnosis is Graves’ disease, thus a thyroid scintigraphy 
or determination of TSH-receptor antibodies is advised.138 
The hypothyroid phase, developing approximately four to 
eight months postpartum and usually lasting four to six 
months, is clinically more important.138 After a period of 
postpartum thyroiditis permanent hypothyroidism occurs 
in 12 to 61%. This can also occur after a previous period of 
euthyroidism, so yearly TSH determination is advised in all 
women after a period of postpartum thyroiditis.138 
T H y r o i d  E M E r G E N C i E s
Thyrotoxic crisis
Thyrotoxic crisis is a clinical syndrome characterised by 
a life-threatening thyrotoxicosis. Critical for diagnosis is 
a high level of clinical suspicion. Burch and Wartofsky 
have proposed a scheme that can facilitate diagnosis. 
Tachycardia, fever, gastrointestinal dysfunction and central 
nervous system dysfunction are the most prominent 
features. 139
Mortality is high (10 to 75%) and therefore treatment should 
be instituted immediately in an intensive care unit.139,140 
Treatment should be supportive and thyroid-specific. 
Supportive treatment consists of correction of hyperpyrexia 
with acetaminophen (aspirin can elevate T4 and T3 levels), 
cardiovascular support, treatment of infection and other 
underlying/precipitating conditions.139,140
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Thyroid-specific treatment is aimed at reducing thyroid 
hormone production and action. Thyroid hormone 
synthesis is blocked by antithyroid drugs; both PTU and 
methimazole can be used (PTU 200 to 250 mg every four 
hours or methimazole 30 mg every six hours).139,140 Thyroid 
hormone release is inhibited by iodine: Lugol’s solution 
10 to 15 drops every eight hours or sodium iodide or 
potassium iodide which can be given intravenously 0.5 to 1 
gram every 12 hours.139,140 In order to prevent iodine from 
being used as a substrate for thyroid hormone synthesis 
it should be given at least one hour after the first dose of 
antithyroid drugs.139,140 Inhibition of peripheral T4 to T3 
conversion is produced by giving high-dose intravenous 
glucocorticoids, e.g. hydrocortisone 200 to 300 mg as a 
loading dose followed by 100 mg every eight hours.139,140 
Blocking the effects of T4 and T3 on peripheral tissues is 
achieved by b-blockers; propranolol is the classic drug for 
this indication: 0.5 to 1.0 mg intravenously in ten minutes 
followed by 1 to 3 mg every hour until concomitantly 
administered oral propranolol (60 to 80 mg every six to 
eight hours) is effective.139,140
How to do it box 14
Treatment of thyrotoxic crisis
Block thyroid hormone synthesis: PTU: 200 to 250 mg • 
every 4 hours or methimazole 30 mg every 6 hours
Inhibit thyroid hormone release – only after • 
administration of antithyroid drugs: Lugol’s solution 10 
to 15 drops every 8 hours or sodium iodide or potassium 
iodide intravenously 0.5 to 1 gram every 12 hours 
Inhibit T4 to T3 conversion: glucocorticoids, e.g. • 
hydrocortisone 200 to 300 mg as a loading dose 
followed by 100 mg every 8 hours
• Block the effects of T4 and T3 on peripheral tissues: 
b-blockers, e.g. propranolol: 0.5-1.0 mg intravenously 
in 10 minutes followed by 1-3 mg every hour until 
concomitantly administered oral propranolol (60-80 
mg every 4 to 6 hours) is effective
Myxoedema coma
Myxoedema coma is a severe state of hypothyroidism 
that presents with altered mental status, respiratory 
insufficiency and hypothermia besides other common 
hypothyroid symptoms.141 It is commonly precipitated 
by an acute event (e.g. infection, myocardial infarction, 
hypothermia, sedatives) on the background of a 
long-standing untreated – or insufficiently treated – 
hypothyroidism.141 Laboratory investigation shows 
hyponatraemia, anaemia, hypoglycaemia, hyperchol-
esterolemia, elevated LDH and creatinine kinase.141 If 
secondary hypothyroidism is suspected hydrocortisone 
should also be given.141 However, to establish the diagnosis 
determination of TSH and fT4 are essential; in this respect 
it is important to be aware that TSH levels can be only 
slightly elevated as a result of nonthyroidal illness. 
Treatment should take place in an intensive care unit.141 
Thyroid hormone substitution should not be delayed 
until results of thyroid function tests are known. We 
advise supplementation of T4 and T3. T4: a loading dose 
of 200 to 250 mg intravenously followed by 100 mg after 
24 hours and thereafter 50 mg daily (preferably oral 
otherwise intravenously). T3: 10 mg every eight hours until 
normalisation of vital function.
How to do it box 15
Treatment of myxoedema coma
T4: a loading dose of 200 to 250 • mg intravenously 
followed by 100 mg after 24 hours and thereafter 50 mg 
daily preferably orally
 • T3: 10 mg every 8 hours until normalisation of vital 
functions
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